» Articles » PMID: 19622457

Azithromycin Reduces Tumor Necrosis Factor-alpha Production in Lipopolysaccharide-stimulated THP-1 Monocytic Cells by Modification of Stress Response and P38 MAPK Pathway

Overview
Journal J Chemother
Date 2009 Jul 23
PMID 19622457
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Macrolide antibiotics are known to have a variety of immunomodulatory effects in addition to antimicrobial activity, but the mechanisms of immunomodulation are still unclear. We investigated in vitro the effect of azithromycin on tumor necrosis factor alpha (TNF-alpha) production in lipopolysaccharide (LPS)-stimulated THP-1 cells, a human monocytic cell line, and compared the results with those for other macrolides, minocycline and ofloxacin. In the presence of LPS, treatment with azithromycin (AZM) resulted in a significant decrease in LPS-induced TNF-alpha production compared to that with other antimicrobial agents. the results of phosphorylation of three MAPKs, ERK, JNK and p38, indicated that the phospho-p38 level was reduced by AZM. Ikappab-alpha, an inhibitor of NFkappab, was not disrupted by the antibiotics. LPS-induced TNF-alpha release from THP-1 cells was inhibited in the presence of KNK437, a potent 70-kDa heat shock protein (HSP-70) inhibitor. Interestingly, the induction of HSP-70 by LPS was attenuated with the concurrent addition of AZM in the cells. AZM was found to restrain TNF-alpha production by monocytes at least in part by modifying the HSp-70 and p38 related signaling pathways to LPS stimulation.

Citing Articles

Investigating the immunomodulatory activities of omadacycline.

Bryant A, Stevens D J Antimicrob Chemother. 2022; 78(1):78-83.

PMID: 36272138 PMC: 9780547. DOI: 10.1093/jac/dkac356.


Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?.

Mohanta T, Arina P, Sharma N, Defilippi P Am J Transl Res. 2021; 12(12):7702-7708.

PMID: 33437355 PMC: 7791480.


Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid-dependent nephrotic syndrome.

Sawires H, Abdelaziz H, Ahmed H, Botrous O, Agban M Pediatr Nephrol. 2019; 34(9):1591-1597.

PMID: 31089818 DOI: 10.1007/s00467-019-04251-5.


Azithromycin does not improve disease severity in acute experimental pancreatitis.

Weis S, Heindl M, Carvalho T, Jentho E, Lorenz J, Sommerer I PLoS One. 2019; 14(5):e0216614.

PMID: 31075097 PMC: 6510415. DOI: 10.1371/journal.pone.0216614.


Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik J, Jutz S Sci Rep. 2014; 4:7438.

PMID: 25500904 PMC: 4262884. DOI: 10.1038/srep07438.